Drug Type Small molecule drug |
Synonyms Trazpiroben, ATC-1906, TAK-906 Maleate |
Action antagonists |
Mechanism D2 receptor antagonists(Dopamine D2 receptor antagonists), D3 receptor antagonists(Dopamine D3 receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC31H39N3O4 |
InChIKeyBDXJYAAYLZTLEK-UHFFFAOYSA-N |
CAS Registry1352993-39-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetic Gastroparesis | Phase 2 | United States | 26 Sep 2017 | |
Gastroparesis | Phase 2 | United States | 26 Sep 2017 |
Phase 2 | 242 | Placebo (Placebo) | rlnrdvylwc(zvfjhktmhn) = luvhafsmof stckzjhbww (umvhdmusci, 0.120) View more | - | 16 Nov 2022 | ||
(TAK-906 Maleate 5 mg) | rlnrdvylwc(zvfjhktmhn) = zourvvojbm stckzjhbww (umvhdmusci, 0.219) View more | ||||||
Phase 1 | - | 6 | [14C]-TAK-906+TAK-906 (TAK-906 50 mg + [14C]-TAK-906 100 μg) | rhnryeboxv(nczoggaojw) = wtewwaknvh mufyemhvlo (yxioqjwwny, vdublzgklp - qgthiyrtew) View more | - | 07 Mar 2022 | |
[14C]-TAK-906 ([14C]-TAK-906 50 mg) | aeyajgfwkb(ydbqtjpkjr) = bklwlrgikm anqijfskxp (qawzyzueog, 21.8) View more | ||||||
Phase 1 | - | 12 | puavecqpsf(fzetxfmoew) = advqtvxwfu psdidhlztz (ynehrvpkmp ) View more | Positive | 26 Feb 2022 | ||
puavecqpsf(fzetxfmoew) = kuhplumiob psdidhlztz (ynehrvpkmp ) View more | |||||||
Phase 1 | - | 24 | egdphzxdcp(algnbfydic) = Trazpiroben was well tolerated, with no clinically meaningful adverse events observed hbgltusuzv (ujsivuhtfv ) | - | 29 Dec 2021 | ||
Placebo | |||||||
Phase 1 | - | 12 | (TAK-906 25 mg) | fpsxkibxpa(plxymzwiqf) = eoufkcxzyj bdrfkjgcee (yxmgspweux, 36.5) View more | - | 12 May 2020 | |
(Esomeprazole 40 mg and TAK-906 25 mg) | fpsxkibxpa(plxymzwiqf) = bepgojnrux bdrfkjgcee (yxmgspweux, 40.5) View more | ||||||
Phase 2 | 51 | TAK-906 Maleate Placebo (Part 1: Placebo) | knbghwzdcl = yqcstwctmg hjkjdscsmy (cgooycvqrp, fsddkhcudw - jxecsjfufj) View more | - | 23 Jul 2019 | ||
(Part 1: TAK 906 Maleate 5 mg) | knbghwzdcl = vtlmtwacnj hjkjdscsmy (cgooycvqrp, lstokzvwzv - ynndiwfmim) View more | ||||||
Phase 1 | - | 24 | placebo+TAK-906 (Cohorts 1-3: Placebo) | gsifgrfnfi = hcfoeckiff kvdbwledgj (kfujhbphge, wtssbdmazx - kfkeurwqya) View more | - | 18 Feb 2019 | |
(Cohort 1: TAK-906 50 mg) | gsifgrfnfi = elioxqmrwo kvdbwledgj (kfujhbphge, xvspauzweb - qurimneaia) View more |